Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ
3.37
+0.09 (+2.74%)
Closed
Oct 9, 2026
Day's Range
3.193.44
52 wk Range
2.428.51
Financial Statements - IMDX - Insight Molecular Diagnostics Inc.
Revenue
4.05M▲ 115.6%
Net Income
-50.22M▲ 17.2%Net Margin -1238.5%
EBITDA
-27.37M▼ 29.0%
Free Cash Flow
-25.36M▼ 19.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 4.05M | 1.88M |
| Cost of Goods | 1.75M | 1.14M |
| Gross Profit | 2.29M | 740K |
 Operating Expense | - | - |
| Operating Income | -30.57M | -23.24M |
| Non-Operating Interest | - | - |
| Other Income Expense | -19.53M | -37.33M |
| Pre Tax Income | -50.22M | -60.66M |
| Income Tax | - | - |
| Net Income | -50.22M | -60.66M |
| EPS Basic | -1.65 | -4.66 |
| EPS Diluted | -1.65 | -4.66 |
| Basic Shares Outstanding | 30.47M | 13.07M |
| Diluted Shares Outstanding | 30.47M | 13.07M |
| Ebit | -50.11M | -60.57M |
| Ebitda | -27.37M | -21.22M |
| Net Income Continuous Operations | -50.22M | -60.66M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
